MTK 458
Alternative Names: MTK-458Latest Information Update: 28 Apr 2025
At a glance
- Originator Mitokinin
- Developer AbbVie
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Protein-serine-threonine kinase stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Huntington's disease; Mitochondrial disorders; Parkinson's disease
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Apr 2025 No recent reports of development identified for preclinical development in Huntington's-disease in USA
- 28 Apr 2025 No recent reports of development identified for preclinical development in Mitochondrial disorders in USA